Erythema multiforme - Erythema Ioma-Chruthhttps://en.wikipedia.org/wiki/Erythema_multiforme
Is e suidheachadh craiceann a th’ ann an Erythema Ioma-Chruth (Erythema multiforme) a tha a’ nochdadh le badan dearga a’ fàs gu bhith nan “target lesions” (mar as trice tha an lesion air an dà làmh). Is e seòrsa de erythema a th’ ann a dh’ fhaodadh a bhith air a mheadhanachadh le galair no nochdadh dhrogaichean.

Tha an suidheachadh ag atharrachadh bho bhroth tlàth, fèin-chuingealaichte gu cruth cruaidh a tha a’ bagairt air beatha ris an canar erythema multiforme major a tha cuideachd a’ toirt a-steach fileagan mucous. Tha ionnsaigh air an membran mucous no làthaireachd bullaes nan comharran cudromach de dhragh.

- Erythema multiforme minor: targaidean àbhaisteach no àrdaichte, papules edematous air an sgaoileadh gu h-acrally
Mar as trice bidh an cruth tlàth a’ nochdadh beagan tachais (ach faodaidh tachas a bhith gu math dona), blotches pinc-dearg, air an rèiteachadh gu co-chothromach agus a’ tòiseachadh air na h-oirean. Tha fuasgladh na broth taobh a-staigh 7-10 latha mar an àbhaist anns an fhoirm seo den ghalar.

- Erythema multiforme major: targaidean àbhaisteach no àrdaichte, papules edematous air an cuairteachadh gu h-acrally le com-pàirt aon no barrachd membran mucous. Tha sgaradh epidermal a’ toirt a-steach nas lugha na 10% de raon uachdar iomlan a’ chuirp.

làimhseachadh ― OTC Drugs
Ma tha fiabhras ann (teòthachd bodhaig ag èirigh), thathas a’ moladh tadhal air an ospadal cho luath ‘s a ghabhas.
Bu chòir stad a chur air drogaichean a tha fo amharas. (me antibiotics, drogaichean neo-steroidal anti-inflammatory)
Antihistamines beòil leithid cetirizine agus loratadine airson tachas fhèin.
#Cetirizine [Zytec]
#LevoCetirizine [Xyzal]
#Loratadine [Claritin]
☆ Ann an toraidhean 2022 Stiftung Warentest às a’ Ghearmailt, cha robh sàsachd luchd-cleachdaidh le ModelDerm ach beagan nas ìsle na le co-chomhairlean telemedicine pàighte.
  • Erythema multiforme minor ― Thoir an aire gum faod ionadan nan lotan a dhol a-mach.
  • Targaid leòintean air a' chas
  • Faodar Urticaria a mheas cuideachd mar dhearbhadh eadar-dhealaichte.
  • Targaid lesion Erythema Ioma-Chruth (Erythema multiforme) - Dh’ fhaodadh e cuideachd a bhith na chomharra tràth de TEN, a dh’ adhbhraicheas blisters farsaing.
  • Taisbeanadh àbhaisteach de Erythema Ioma-Chruth (Erythema multiforme)
  • Bu chòir beachdachadh cuideachd air galar Lyme. cf) Bulls eye of Lyme Disease Rash
References Recent Updates in the Treatment of Erythema Multiforme 34577844 
NIH
Tha Erythema multiforme (EM) na chumha far am bi spotan sònraichte coltach ri targaid a’ nochdadh an dà chuid air a’ chraiceann agus air na membranan mucous mar thoradh air ath-bhualaidhean dìonachd. Ged a tha e tric air a bhrosnachadh le galairean viral, gu sònraichte bhìoras herpes simplex (HSV) , no cuid de chungaidh-leigheis, tha an adhbhar fhathast neo-aithnichte ann an iomadh cùis. Le bhith a’ làimhseachadh EM acute tha fòcas air a bhith a’ lughdachadh comharraidhean le bhith a’ cleachdadh uachdaran anns a bheil steroids no antihistamines. Tha a bhith a’ riaghladh EM ath-chuairteachaidh nas èifeachdaiche nuair a thèid a dhealbhadh airson gach euslainteach. Tha dòighean-obrach tùsail a’ toirt a-steach làimhseachadh beòil agus làitheil. Nam measg tha corticosteroids agus cungaidhean anti-bhìorais. Tha làimhseachadh cuspaireil a’ toirt a-steach uachdaran steroid làidir agus fuasglaidhean airson membran mucous air a bheil buaidh. Dha euslaintich nach eil a’ freagairt air anti-bhìorasan, tha roghainnean dàrna loidhne a’ toirt a-steach drogaichean dìon-dìon, antibiotics, anthelmintics, agus antimalarials.
Erythema multiforme (EM) is an immune-mediated condition that classically presents with discrete targetoid lesions and can involve both mucosal and cutaneous sites. While EM is typically preceded by viral infections, most notably herpes simplex virus (HSV), and certain medications, a large portion of cases are due to an unidentifiable cause. Treatment for acute EM is focused on relieving symptoms with topical steroids or antihistamines. Treatment for recurrent EM is most successful when tailored to individual patients. First line treatment for recurrent EM includes both systemic and topical therapies. Systemic therapies include corticosteroid therapy and antiviral prophylaxis. Topical therapies include high-potency corticosteroids, and antiseptic or anesthetic solutions for mucosal involvement. Second-line therapies for patients who do not respond to antiviral medications include immunosuppressive agents, antibiotics, anthelmintics, and antimalarials
 Use of steroids for erythema multiforme in children 16353829 
NIH
Ann an iomadh suidheachadh, bidh erythema multiforme tlàth a’ falbh leis fhèin taobh a-staigh 2 gu 4 seachdainean. Faodaidh syndrome Stevens-Johnson, droch staid a bheir buaidh air fileagan mucous, mairsinn suas ri 6 seachdainean. Mar as trice chan eilear a’ moladh steroids airson cùisean tlàth. Chan eil cinnt co-dhiù a bu chòir steroids a chleachdadh airson erythema multiforme trom, leis nach eil toraidhean soilleir ann bho sgrùdaidhean air thuaiream a 'sealltainn dè a' chlann a gheibheadh ​​​​buannachd bhon leigheas seo.
In most cases, mild erythema multiforme is self-limited and resolves in 2 to 4 weeks. Stevens-Johnson syndrome is a serious disease that involves the mucous membranes and lasts up to 6 weeks. There is no indication for using steroids for the mild form. Use of steroids for erythema multiforme major is debatable because no randomized studies clearly indicate which children will benefit from this treatment.
 Drug-induced Oral Erythema Multiforme: A Diagnostic Challenge 29363636 
NIH
Bidh sinn a’ taisbeanadh cùis de erythema multiforme (EM) beòil air adhbhrachadh le TMP/SMX , a’ sealltainn ulcers beòil is bilean àbhaisteach gun lotan craiceann. Tha seo a’ daingneachadh an fheum air a dhealachadh bho eas-òrdughan beul-aithris eile. Fhuair an t-euslainteach làimhseachadh samhlachail agus clàran prednisolone, a lean gu leasachadh às deidh stad a chuir air TMP / SMX therapy.
We report a case of oral erythema multiforme (EM) secondary to TMP/SMX that presented with oral and lip ulcerations typical of EM without any skin lesions and highlights the importance of distinguishing them from other ulcerative disorders involving oral cavity. The patient was treated symptomatically and given tablet prednisolone. The condition improved with stoppage of TMP/SMX therapy.
 Erythema Multiforme: Recognition and Management. 31305041
Tha Erythema multiforme na fhreagairt a tha a’ toirt a-steach a’ chraiceann agus uaireannan am mucosa, air a phiobrachadh leis an t-siostam dìon. Mar as trice, bidh e a’ nochdadh mar leòintean coltach ri targaid, a dh’ fhaodadh a bhith a’ nochdadh aonaranach, a’ tighinn air ais no a’ leantainn. Mar as trice bidh na leòintean sin a’ toirt buaidh cho-chothromach air na h-iomaill, gu sònraichte an uachdar a-muigh. Am measg nam prìomh adhbharan tha galairean leithid bhìoras herpes simplex agus Mycoplasma pneumoniae, a bharrachd air cuid de chungaidh-leigheis, banachdach, agus galairean fèin-dìon. Tha eadar-dhealachadh erythema multiforme bho urticaria an urra ri fad nan lotan; erythema multiforme leòintean fhathast stèidhichte airson co-dhiù seachd latha, agus bidh lotan urticrial gu tric a’ dol à sealladh taobh a-staigh latha. Ged a tha e coltach, tha e deatamach eadar-dhealachadh a dhèanamh eadar erythema multiforme bhon t-syndrome Stevens-Johnson nas cruaidhe, a bhios mar as trice a’ toirt a-steach maculan erythematous no purpuric farsaing le blisters. Tha riaghladh erythema multiforme a’ toirt a-steach faochadh samhlachail le steroids gnàthach no antihistamines agus dèiligeadh ris a’ bhun-adhbhar. Airson cùisean ath-chuairteachaidh co-cheangailte ri bhìoras herpes simplex, thathar a ‘moladh leigheas anti-bhìoras prophylactic. Dh’ fhaodadh gum bi feum air fìor dhroch cheangal mucosal airson ospadal airson lionntan intravenous agus ath-chur electrolyte.
Erythema multiforme is a reaction involving the skin and sometimes the mucosa, triggered by the immune system. Typically, it manifests as target-like lesions, which may appear isolated, recur, or persist. These lesions usually symmetrically affect the extremities, particularly their outer surfaces. The main causes include infections like herpes simplex virus and Mycoplasma pneumoniae, as well as certain medications, immunizations, and autoimmune diseases. Distinguishing erythema multiforme from urticaria relies on the duration of lesions; erythema multiforme lesions remain fixed for at least seven days, while urticarial lesions often vanish within a day. Although similar, it's crucial to differentiate erythema multiforme from the more severe Stevens-Johnson syndrome, which typically presents widespread erythematous or purpuric macules with blisters. Managing erythema multiforme involves symptomatic relief with topical steroids or antihistamines and addressing the underlying cause. For recurrent cases associated with herpes simplex virus, prophylactic antiviral therapy is recommended. Severe mucosal involvement may necessitate hospitalization for intravenous fluids and electrolyte replacement.